Eike C. Buss, MD

SVP Clinical Development at Apogenix AG at Apogenix AG
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Heidelberg, Baden-Württemberg, Germany, DE
Languages
  • English Full professional proficiency
  • German Native or bilingual proficiency
  • French Limited working proficiency
  • Hebrew Elementary proficiency
  • Latin Limited working proficiency
Skills

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • General Medical Council (GMC, UK) specialist registration for general (internal) medicine and haematology and licence to practise
    General Medical Council (GMC, UK)
    May, 2021
    - Nov, 2024
  • Subspecialty Hematology/Oncology; in German: Schwerpunkt Hämatologie/Onkologie
    The State Chamber of Physicians of Baden-Württemberg (Board); in German: Landesärztekammer BW
    Jan, 2015
    - Nov, 2024
  • Specialty Internal Medicine; in German: Facharzt für Innere Medizin
    The State Chamber of Physicians of Baden-Württemberg (Board); in German: Landesärztekammer BW
    Sep, 2011
    - Nov, 2024
  • United States Medical Licensing Examination, USMLE Step 2, "Clinical Knowledge"
    USMLE, ECFMG
    Jun, 2005
    - Nov, 2024
  • Dr. med. title
    University of Heidelberg, Faculty of Medicine; grade "magna cum laude"
    Dec, 2003
    - Nov, 2024
  • Medical license; in German: volle Approbation
    State authority Baden-Württemberg, Germany
    Jan, 2003
    - Nov, 2024
  • United States Medical Licensing Examination, USMLE Step 1
    USMLE, ECFMG
    Jun, 1998
    - Nov, 2024

Experience

  • Apogenix GmbH
    • Biotechnology Research
    • 1 - 100 Employee
    • SVP Clinical Development at Apogenix AG
      • Dec 2022 - Present

      Our heavy-lift randomized Phase 3 Covid-19 ASUCOV trial of asunercept has started recruiting!We are still happy to include more sites in Germany, Austria, Poland, France, Spain, Italy, India, South Africa and Georgia.PR: https://apogenix.com/files/Pressemitteilungen/20221214_PR_Apogenix_First_Patients_In_ACUCOV_ENG.pdfCT gov: https://clinicaltrials.gov/ct2/show/NCT05639192Built on the Phase 2 results for asunercept in Covid-19: “The combined asunercept dose groups (25, 100 and 400 mg arms) revealed statistically significant faster clinical improvement compared to SOC group (p= 0.038; HR=1.37)”. https://apogenix.com/files/AsunerceptDemonstratesEfficacyPhaseII.pdf Show less

    • VP Clinical Development
      • May 2022 - Nov 2022

  • AstraZeneca
    • United Kingdom
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Senior Global Dev. Med. Director
      • May 2021 - Apr 2022

    • Global Development Medical Director
      • Mar 2021 - Apr 2021

    • Associate Director Physician
      • Apr 2020 - Feb 2021

  • AbbVie
    • United States
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Associate Medical Director, Global Oncology Development
      • Jul 2016 - Apr 2020

  • University Hospital Heidelberg
    • Germany
    • 200 - 300 Employee
    • Medical Doctor, Attending, Specialist for Hematology/Oncology
      • Jan 2009 - Jun 2016

  • Weizmann Institute of Science
    • Israel
    • Research
    • 700 & Above Employee
    • Postdoctoral Fellow
      • Apr 2006 - Dec 2008

  • University Hospital Heidelberg
    • Germany
    • 200 - 300 Employee
    • Medical Doctor
      • Jul 2001 - Mar 2006

Education

  • DKFZ German Cancer Research Center
    Doctor of Medicine (M.D.)
    1998 - 2003
  • The University of Manchester
    Doctor of Medicine (M.D.)
    1997 - 1998
  • Heidelberg University
    Doctor of Medicine (M.D.)
    1994 - 2001
  • Geschwister-Scholl-Gymnasium, Ludwigshafen am Rhein, Germany
    Abitur (maturity diploma)
    1984 - 1993

Community

You need to have a working account to view this content. Click here to join now